Neural Changes in the Aging Auditory System

December 8, 2005 updated by: University of Rochester

Age-Related Hearing Loss: Presbycusis & Its Neural Bases

The purpose of this study was to determine the effects of hormone replacement therapy (HRT) on hearing in post-menopausal women.

Study Overview

Detailed Description

Background: Female hormone influences on the development and aging of the auditory system are not completely understood. The present study retrospectively analyzed and compared hearing abilities among post-menopausal women taking hormone replacement therapy (HRT), treated with estrogen and progesterone (E+P); estrogen alone (E), and a third (control - NHRT) group, matched for age, who did not receive any HRT.

Methods: 126 subjects, (60-86 yr), N=32, E+P; N=31, E; N= 63, NHRT; matched for age and health status participated. All had relatively healthy medical histories, absence of significant noise exposure, middle ear problems, major surgeries or current/heavy smoking. Hearing tests included pure tone audiometry (PTA), tympanometry, distortion-product otoacoustic emissions (DPOAEs), transient otoacoustic emissions (TEOAEs) and hearing-in-noise-test (HINT). The latter is a test for speech perception in background noise: the major complaint of hearing-impaired persons.

.

Study Type

Observational

Enrollment

126

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Rochester, New York, United States, 14642
        • University of Rochester Medical Center
      • Rochester, New York, United States, 14623-5604
        • International Center Hearing & Speech Research - NTID - RIT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 86 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Healthy middle ears

Exclusion Criteria:

  • ototoxic medications
  • serious medical health problems
  • neurological conditions
  • Meniere's disease or labyrinthitis
  • those who failed cognitive screening tests (Mini-Mental Test)
  • current/heavy smokers
  • conductive hearing loss
  • history of noise damage and/or audiograms signifying noise damage
  • poor speech discrimination scores (80% or less)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Robert D Frisina, Ph.D., University of Rochester Medical School

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2001

Study Completion

February 1, 2005

Study Registration Dates

First Submitted

December 8, 2005

First Submitted That Met QC Criteria

December 8, 2005

First Posted (ESTIMATE)

December 12, 2005

Study Record Updates

Last Update Posted (ESTIMATE)

December 12, 2005

Last Update Submitted That Met QC Criteria

December 8, 2005

Last Verified

December 1, 2005

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Progesterone

Clinical Trials on Hormone Replacement Therapy - HRT

3
Subscribe